Emission reduction strategies and health: a systematic review on the tools and methods to assess co-benefits

Sammila Andrade Abdala,Kenza Khomsi,Anass Houdou,Ihssane El Marouani,Imad El Badisy,Houda Najmi,Majdouline Obtel,Lahcen Belyamani,Azeddine Ibrahimi,Mohamed Khalis
DOI: https://doi.org/10.1136/bmjopen-2023-083214
IF: 3.006
2024-12-11
BMJ Open
Abstract:Objective The objective of this study is to review the current literature on the health co-benefits of emission reduction strategies and the methods and tools available to assess them. Design Systematic review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data sources PubMed, Scopus, Web of Science, ScienceDirect and GreenFILE were searched from January of 2017 to March of 2023. Eligibility criteria We included original, peer-reviewed journal articles that described emission (ambient air pollutant and greenhouse gases) reduction strategies and assessed their health co-benefits. Data extraction and synthesis Two independent reviewers employed standardised methods to search, screen and code the included studies, documenting their findings in an Excel spreadsheet. Results From 6687 articles, 82 were included. Most studies show that emissions reduction strategies improve air quality, reducing mortality and morbidity. Health risk assessment and health impact assessment are common, though procedures may cause confusion. About 33% used established models like the integrated exposure-response and global exposure mortality model. Out of all studies, 16% of them used Environmental Benefits Mapping and Analysis Program—Community Edition. Only 17.8% carried out cost–benefit analyses, but these show economic worth in investing in emission reduction strategies. Conclusions Emission reduction strategies significantly enhance human health, with potential co-benefits offsetting intervention costs, which can be an incentive for action in low and middle-income countries. This review emphasises investing in cost–benefit analyses and research, particularly in regions with limited studies on emission reduction and health co-benefits. It provides decision-makers insights into selecting assessment methods and underscores the ongoing need for model and tool evaluation. PROSPERO registration number CRD42022332480.
medicine, general & internal
What problem does this paper attempt to address?